Research Analysts’ Weekly Ratings Changes for Monsanto (MON)

A number of research firms have changed their ratings and price targets for Monsanto (NYSE: MON):

  • 9/15/2017 – Monsanto had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $128.00 price target on the stock.
  • 9/14/2017 – Monsanto was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $132.00 price target on the stock. According to Zacks, “Monsanto's shares have outperformed the industry in a year's time. The company reported better-than-expected results for third-quarter fiscal 2017. Increasing demand for crop-yield enhancing products, such as Roundup Ready 2 Xtend Soybeans, and launch of non-imitable technological solutions are likely to boost the company's top-line performance, moving ahead. Further, robust top-line performance, higher planted acreage, as well as lower U.S. corn and soybean costs are expected to bolster bottom-line results in near term. Also, the successful accomplishment of Bayer's buyout deal is anticipated to open up a number of opportunities for Monsanto. Over the last 60 days, the Zacks Consensus Estimate for the stock moved north for fiscal 2018.”
  • 9/12/2017 – Monsanto was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last twelve months, Monsanto’s shares outperformed the industry. The company reported better-than-expected third-quarter fiscal 2017 results. Increasing demand for crop-yield enhancing products, stronger innovation and success of Bayer’s buyout deal are anticipated to bolster Monsanto’s top- and bottom-line performance in the quarters ahead. However, challenging pricing conditions prevailing in the agricultural market might limit near-term growth. In addition, headwinds like weaker currencies of major overseas markets, such as Brazil, or stiff industry rivalry remain major causes of worry. Over the last 30 days, Zacks Consensus Estimate for the stock has remained unchanged for fiscal 2018.”
  • 9/5/2017 – Monsanto was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last twelve months, Monsanto's shares outperformed the industry. The company reported better-than-expected third-quarter fiscal 2017 results. Increasing demand for crop-yield enhancing products, stronger innovation and success of Bayer's buyout deal are anticipated to bolster Monsanto's top- and bottom-line performance in the quarters ahead. However, challenging pricing conditions prevailing in the agricultural market might limit near-term growth. In addition, headwinds like weaker currencies of major overseas markets, such as Brazil, or stiff industry rivalry remain major causes of worry. Over the last 30 days, Zacks Consensus Estimate for the stock has remained unchanged for fiscal 2018.”
  • 9/4/2017 – Monsanto was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $131.00 price target on the stock. According to Zacks, “Monsanto’s shares have outperformed the industry in a year’s time. The company reported better-than-expected results for third-quarter fiscal 2017. Increasing demand for crop-yield enhancing products, such as Roundup Ready 2 Xtend Soybeans, and launch of non-imitable technological solutions are likely to boost the company’s top-line performance, moving ahead.  Further, robust top-line performance, higher planted acreage, as well as lower U.S. corn and soybean costs are expected to bolster bottom-line results in near term. Also, the successful accomplishment of Bayer’s buyout deal is anticipated to open up a number of opportunities for Monsanto. Over the last 60 days, the Zacks Consensus Estimate for the stock moved north for fiscal 2018.”
  • 9/1/2017 – Monsanto had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $128.00 price target on the stock.
  • 8/30/2017 – Monsanto was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last twelve months, Monsanto's shares outperformed the industry. The company reported better-than-expected third-quarter fiscal 2017 results. Increasing demand for crop-yield enhancing products, stronger innovation and success of Bayer's buyout deal are anticipated to bolster Monsanto's top- and bottom-line performance in the quarters ahead. However, challenging pricing conditions prevailing in the agricultural market might limit near-term growth. In addition, headwinds like weaker currencies of major overseas markets, such as Brazil, or stiff industry rivalry remain major causes of worry. Over the last 30 days, Zacks Consensus Estimate for the stock has remained unchanged for fiscal 2018.”
  • 8/29/2017 – Monsanto was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $131.00 price target on the stock. According to Zacks, “Over the last six months, Monsanto’s shares outperformed the industry. The company reported better-than-expected third-quarter fiscal 2017 results. Increasing demand for crop-yield enhancing products, stronger innovation and success of Bayer’s buyout deal are anticipated to bolster Monsanto’s top- and bottom-line performance in the quarters ahead. However, challenging pricing conditions prevailing in the agricultural market might limit near-term growth. In addition, headwinds like weaker currencies of major overseas markets, such as Brazil, or stiff industry rivalry remain major causes of worry. Over the last seven days, Zacks Consensus Estimate for the stock has remained unchanged for both fiscal 2017 and 2018.”
  • 8/19/2017 – Monsanto was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/18/2017 – Monsanto was downgraded by analysts at UBS AG from a “buy” rating to a “neutral” rating. They now have a $128.00 price target on the stock.
  • 8/11/2017 – Monsanto was given a new $128.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 8/2/2017 – Monsanto had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $128.00 price target on the stock.
  • 8/2/2017 – Monsanto was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $122.35 price target on the stock.

Shares of Monsanto Company (MON) opened at 119.41 on Wednesday. The company has a market cap of $52.46 billion, a price-to-earnings ratio of 25.79 and a beta of 1.07. The firm has a 50 day moving average price of $117.37 and a 200-day moving average price of $116.53. Monsanto Company has a 52-week low of $97.35 and a 52-week high of $119.60.

Monsanto (NYSE:MON) last posted its earnings results on Wednesday, June 28th. The basic materials company reported $1.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.74 by $0.19. The company had revenue of $4.23 billion for the quarter, compared to analysts’ expectations of $4.18 billion. Monsanto had a return on equity of 45.26% and a net margin of 14.11%. Monsanto’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period last year, the firm earned $2.17 earnings per share. Equities research analysts anticipate that Monsanto Company will post $4.89 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, October 6th will be issued a $0.54 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $2.16 annualized dividend and a yield of 1.81%. Monsanto’s dividend payout ratio (DPR) is presently 46.75%.

In other news, EVP Steven Mizell sold 11,300 shares of Monsanto stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $118.57, for a total transaction of $1,339,841.00. Following the completion of the transaction, the executive vice president now directly owns 55,011 shares in the company, valued at $6,522,654.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Robert T. Fraley sold 52,410 shares of Monsanto stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $117.95, for a total transaction of $6,181,759.50. The disclosure for this sale can be found here. Company insiders own 0.79% of the company’s stock.

Monsanto Company (Monsanto), along with its subsidiaries, is a provider of agricultural products for farmers. The Company provides seeds, biotechnology trait products, herbicides and digital agriculture tools to farmers. The Company operates through two segments: Seeds and Genomics, and Agricultural Productivity.

Receive News & Ratings for Monsanto Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monsanto Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply